Epigenomics

How ketamine may change gene activity to help treat depression: a systematic review

Updated

Abstract

Eighteen studies suggest ketamine may have lasting effects on depression through epigenetic changes.

  • Most preclinical studies indicated that ketamine may influence histone acetylation and methylation, enhancing the expression of genes related to neuroplasticity.
  • Six studies pointed to the role of non-coding RNAs, especially microRNAs, in maintaining antidepressant effects.
  • Five studies found that ketamine could reverse hypermethylation in genes associated with synaptic signaling and stress, including brain-derived neurotrophic factor.
  • These effects appeared strongest in brain regions important for emotional control, such as the hippocampus and medial prefrontal cortex.
  • Indirect epigenetic mechanisms may also affect circadian clock and inflammation-related genes.
  • While preclinical results are promising, the limited human data suggest a need for further studies to understand these mechanisms in clinical settings.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. No writing assistance was utilized in the production of this manuscript.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free